Last updated on November 2019

A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female

Inclusion Criteria:

  • Age >/= 18 years
  • Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV)
  • Pathologically confirmed HER2-positive breast cancer
  • Planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last weeks with a planned duration of at least 12 months.
  • Normal LV systolic function (EF greater than or equal to the institutional lower limit of normal)
  • William and able to comply with the requirements of the protocol

Exclusion Criteria:

  • Planned to receive an anthracycline-based regimen
  • Prior history of treatment with anthracycline chemotherapy
  • History of cardiovascular including cardiomyopathy, heart failure, or any other clinically significant cardiovascular disease (as determined by the investigator)
  • Uncontrolled hypertension, defined as systolic blood pressure >/= 160 mmHg and/or diastolic blood pressure >/= 90 mmHg (as determined by the investigator)

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.